Abstract
Background Healthcare expenditures continue to rise, and hospitalization costs remain the driving factor for nationally increasing health expenditures.(1,3) Affordability initiatives targeted at minimizing inpatient drug spending and medication waste are vital. Metered dose-inhalers (MDIs) impose high potential for medication waste as their bulk nature provides a day supply that far exceeds average hospitalization length of stay.(1,7) Kaiser Permanente Baldwin Park Medical Center inpatient pharmacy adopted a cost saving initiative aimed at converting the commonly prescribed ipratropium MDI to its equivalent nebulized solution. Methods This was a retrospective medication use evaluation (MUE), assessing the overall drug cost impact of converting patients from ipratropium MDI to ipratropium nebulized solution. The study period consisted of two phases: the pre-implementation phase from 11/1/2017 to 09/30/2018, and the post-implementation phase from 11/01/2018 to 09/30/2019.The study population consisted of patients admitted to the Critical Care Unit (CCU) and Step-Down Unit (SDU), who were prescribed an ipratropium MDI or ipratropium nebulized solution. Patients who were under the age of 18 years old were excluded. The primary outcome was to analyze the drug cost savings of prescribing nebulized solutions over MDIs in the inpatient setting. The secondary outcome was to assess overall compliance with the conversion protocol. Results Ipratropium MDI administrations declined by 91% (from 3,751 to 336) during the post-implementation phase. An estimated drug cost savings of $68,700 occurred by converting the ipratropium MDIs to ipratropium nebulized solution. Conclusion This conversion protocol was successful at reducing MDI waste and attaining substantial drug cost savings at our medical center over a period of 1 year since implementation.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
